PRO-140 is a humanized anti-CCR5 monoclonal antibody currently in phase II clinical development for the treatment of HIV. It has exhibited potent in vitro antiviral activity against a broad range of HIV-1 isolates. This antiviral activity has been confirmed in a number of clinical studies involving HIV-infected patients, with no drug-related serious adverse events reported.
ASJC Scopus subject areas
- Pharmacology (medical)